Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMID in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival .
http://news.investors.com/newsfeed-business-wire/071113-141502643-phase-iii-study-mm-020ifm-07-01-of-oral-revlimid-lenalidomide-in-newly-diagnosed-multiple-myeloma-meets-primary-endpoint.aspx
http://news.investors.com/newsfeed-business-wire/071113-141502643-phase-iii-study-mm-020ifm-07-01-of-oral-revlimid-lenalidomide-in-newly-diagnosed-multiple-myeloma-meets-primary-endpoint.aspx
No comments:
Post a Comment